Clin2
NCT07306481Possibly a fitNot yet recruiting

Probiotic and immunotherapy before liver cancer surgery

HCC - Hepatocellular Carcinoma

Part of Cancer, Digestive system clinical trials.

This trial tests whether taking a probiotic before surgery together with immunotherapy can improve outcomes for people with liver cancer that can be removed. You must be able to have surgery after the combination treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
40 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer.
  • You will receive immunotherapy before surgery, and then have the tumor removed.
  • You have not had any prior chemotherapy, targeted therapy, or immunotherapy for liver cancer.
  • You have not used probiotics or antibiotics in the last 2 months.
  • You can eat food by mouth and are not on a liquid or restricted diet.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07618546Not yet recruiting
Combination therapy before and after liver cancer surgery

This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.

NCT07475026Recruiting· Phase 3
Combination therapy before surgery for high-risk liver cancer

This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.

Tianjin
NCT07518706Not yet recruiting· Phase 2
Immunotherapy Plus Targeted Drug Before Surgery for Early Liver Cancer

This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.

NCT06492408Recruiting· Phase 2
Immunotherapy before surgery for liver cancer

This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.

Guanzhou, Guangdong
NCT06551272Recruiting· Phase 2
Gut bacteria change to help immunotherapy for liver cancer

This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.

Bobigny
NCT06741020Recruiting· Phase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery

This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.

Hangzhou, Zhejiang

Hear when a new HCC - Hepatocellular Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.